Standardized cannabis extract ( DrugBank: Cannabis )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00552604 (ClinicalTrials.gov) | June 2006 | 1/11/2007 | MUltiple Sclerosis and Extract of Cannabis (MUSEC) Study | Randomised, Double-blind, Placebo-controlled Phase III Trial to Determine the Efficacy and Safety of a Standardised Oral Extract of Cannabis Sativa for the Symptomatic Relief of Muscle Stiffness and Pain in Multiple Sclerosis. | Muscle Spasticity | Drug: standardized cannabis extract;Drug: Placebo | Institut fur Klinische Forschung, Germany | Weleda AG | Terminated | 18 Years | 64 Years | Both | 279 | Phase 3 | United Kingdom |